Mis- and disinformation in the cell and gene therapy industry

Banner featuring Megan Munsie and Samantha Yammine promoting 'Commercializing Living Therapies with CCRM'.
July 15, SEASON 5, EPISODE 1

Mis- and disinformation in the cell and gene therapy industry

How misleading claims, hype and confusion can affect public trust, patient expectations and the broader field.

Banner featuring Megan Munsie and Samantha Yammine promoting 'Commercializing Living Therapies with CCRM'.

Featuring:

Megan Munsie, PhD, Group Leader, Stem Cell Ethics & Policy, Stem Cell Medicine, Murdoch Children’s Research Institute; Prepare Theme Lead, Novo Nordisk Foundation Center for Stem Cell Medicine, reNEW; Professor Emerging Technology (Stem Cells), Melbourne Medical School, University of Melbourne

Samantha Yammine, PhD, neuroscientist, science communicator and digital media creator

***

In this episode, our host, Krista Lamb, speaks with Drs. Megan Munsie and Samantha Yammine about mis- and disinformation in the cell and gene therapy industry. They discuss why the cell and gene therapy field is especially vulnerable to misleading claims and the challenge of separating legitimate progress from hype.

The conversation explores the risks of dis- and misinformation, including public confusion, false expectations and moving from harm to trust in legitimate science. They also examine how regulation, international differences and artificial intelligence can both complicate and potentially support better information sharing.

Looking ahead, the guests consider what industry professionals, companies and regulators can do to respond more effectively. They emphasize responsible communication, stronger public education and cautious optimism about improving trust in the field.

An image of a GMP operator as the thumbnail for CCRM's podcast.

Subscribe to receive an email when a new episode of our podcast is published.

 
 

You have Successfully Subscribed!